Abterra Biosciences, Inc. has developed a drug discovery platform that uses machine learning to mine the immune response of real patients to identify novel therapeutic antibodies. Our platform, Alicanto, delivers antibody therapeutics that have been sourced from patients who overcame infectious diseases and cancer. We have commercialized two predecessor technologies, Reptor and Valens, that we offer as services to support drug discovery at pharma and biotech companies.